Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019
NEW YORK, Oct. 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019
http://www.reportlinker.com/p0925666/Diabetic-Foot-Ulcer-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, "Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Diabetic Foot Ulcers Therapeutics market. The report identifies the key trends shaping and driving the global Diabetic Foot Ulcers Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Diabetic Foot Ulcers Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Diabetic Foot Ulcers Therapeutics market. Its Scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Diabetic Foot Ulcers Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Diabetic Foot Ulcers Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Diabetic Foot Ulcers Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Diabetic Foot Ulcers Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Diabetic Foot Ulcers Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Diabetic Foot Ulcers Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Diabetic Foot Ulcers Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Diabetic Foot Ulcer Therapeutics - Introduction 7
2.1 Overview 7
2.1.1 Diabetic Foot Ulcer Classification Systems 7
2.2 Epidemiology 10
2.2.1 Historic Epidemiology (2006-2011) 10
2.2.2 Forecast Epidemiology (2011-2019) 10
2.3 Prognosis 11
2.4 Etiology 11
2.5 Symptoms 12
2.6 Diagnosis 12
2.6.1 History 12
2.6.2 Neurologic Examination 12
2.6.3 Vascular Examination 13
2.6.4 Musculoskeletal Examination 13
2.6.5 Wound Evaluation 13
2.6.6 Laboratory Testing and Imaging Studies 13
2.7 Pathophysiology 14
2.8 Treatment and Management Pattern 15
2.8.1 Infection Control 15
2.8.2 Mechanical Load Relief 16
2.8.3 Wound Care/Debridement 16
2.8.4 Blood Glucose Control 16
2.8.5 Patient Education 17
2.9 Referral Pathway 17
2.10 GlobalData Pipeline Report Guidance 18
3 Diabetic Foot Ulcer Therapeutics - Market Characterization 19
3.1 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Global 19
3.2 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Global 21
3.3 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - The US 23
3.4 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - The US 25
3.5 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - France 27
3.6 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - France 29
3.7 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Germany 31
3.8 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Germany 33
3.9 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Italy 35
3.10 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Italy 37
3.11 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Spain 39
3.12 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Spain 41
3.13 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - The UK 43
3.14 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - The UK 45
3.15 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Japan 47
3.16 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Japan 49
3.17 Drivers and Barriers for the Diabetic Foot Ulcer Therapeutics Market 51
3.17.1 Drivers of the Diabetic Foot Ulcer Therapeutics Market 51
3.17.2 Barriers for the Diabetic Foot Ulcer Therapeutics Market 52
3.18 Opportunity and Unmet Need 53
3.19 Key Takeaway 54
4 Diabetic Foot Ulcer Therapeutics - Competitive Assessment 55
4.1 Overview 55
4.2 Strategic Competitor Assessment 55
4.3 Product Profiles for the Major Marketed Products in the Diabetic Foot Ulcer Therapeutics Market 57
4.4 Anti-infectives 57
4.4.1 Invanz (ertapenem) 57
4.4.2 Zosyn (piperacillin/tazobactam) 58
4.4.3 Zyvox (linezolid) 59
4.5 Wound-healing Products 60
4.5.1 Regranex (becaplermin) 60
4.6 Key Takeaway 61
5 Diabetic Foot Ulcer Therapeutics - Pipeline Assessment 62
5.1 Overview 62
5.2 Strategic Pipeline Assessment 62
5.3 Diabetic Foot Ulcer Therapeutics - Pipeline Analysis by Phase of Development 62
5.3.1 Diabetic Foot Ulcer Therapeutics - Phase III Pipeline 62
5.3.2 Diabetic Foot Ulcer Therapeutics - Phase II Pipeline 63
5.3.3 Diabetic Foot Ulcer Therapeutics - Phase I Pipeline 64
5.3.4 Diabetic Foot Ulcer Therapeutics - Preclinical and Discovery Pipeline 64
5.4 Diabetic Foot Ulcer Therapeutics - Pipeline by Mechanism of Action 65
5.5 Technology Trends Analytical Framework 67
5.6 Profiles of Promising Drugs 68
5.6.1 CVBT-141B (FGF-1) 68
5.6.2 Fragmin (dalteparin sodium) 69
5.6.3 Trafermin 70
5.6.4 Heberprot-P 70
5.6.5 HO/03/03 71
5.6.6 CureXcell 71
5.7 Key Takeaway 71
6 Diabetic Foot Ulcer Therapeutics - Clinical Trial Mapping 72
6.1 Clinical Trials by Region and Country 72
6.2 Clinical Trials by Phase of Clinical Development 73
6.3 Clinical Trials by Trial Status 74
6.4 Clinical Trials by Sponsors 75
6.5 Top Companies Participating in Diabetic Foot Ulcer Therapeutics Clinical Trials 77
7 Diabetic Foot Ulcer Therapeutics - Strategic Assessment 78
7.1 Key Events Impacting the Future Market 78
7.2 Future Market Competition Scenario 79
8 Diabetic Foot Ulcer Therapeutics - Future Players 81
8.1 Introduction 81
8.2 Company Profiles 81
8.2.1 Pfizer Inc. 81
8.2.2 Cardiovascular Biotherapeutics, Inc. 83
8.2.3 HealOr Ltd. 83
8.2.4 MacroCure Ltd. 84
8.2.5 Other Companies in the Pipeline 84
9 Diabetic Foot Ulcer Therapeutics - Licensing and Partnership Deals 88
10 Diabetic Foot Ulcer Therapeutics - Appendix 89
10.1 Market Definitions 89
10.2 Abbreviations 89
10.3 Bibliography 90
10.4 Physicians and Specialists Included in this Study 92
10.5 Research Methodology 92
10.5.1 Coverage 92
10.5.2 Secondary Research 92
10.5.3 Forecasting 93
10.5.4 Primary Research 95
10.5.5 Expert Panel Validation 96
10.6 Contact Us 96
10.7 Disclaimer 96
List of Tables
Table 1: Diabetic Foot Ulcer - Wagner-Meggitt Classification 7
Table 2: The University of Texas - Diabetic Wound Classification System 8
Table 3: Diabetic Foot Ulcer, Global, Prevalence Population, 2006-2011 10
Table 4: Diabetic Foot Ulcer, Global, Prevalence Population, 2011-2019 10
Table 5: Diabetic Foot Ulcer - Risk Factors 11
Table 6: Diabetic Foot Infections - Empirical Antibiotic Regimens 15
Table 7: Diabetic Foot Infection Therapeutics Market, Global, Revenue ($m), 2006-2011 20
Table 8: Wound-healing Therapeutics Market, Global, Revenue ($m), 2006-2011 20
Table 9: Diabetic Foot Infection Therapeutics Market, Global, Forecast ($m), 2011-2019 21
Table 10: Wound-healing Therapeutics Market, Global, Forecast ($m), 2011-2019 22
Table 11: Diabetic Foot Infection Therapeutics Market, The US, Revenue ($m), 2006-2011 23
Table 12: Wound-healing Therapeutics Market, The US, Revenue ($m), 2006-2011 24
Table 13: Diabetic Foot Infection Therapeutics Market, The US, Forecast ($m), 2011-2019 25
Table 14: Wound-healing Therapeutics Market, The US, Forecast ($m), 2011-2019 26
Table 15: Diabetic Foot Infection Therapeutics Market, France, Revenue ($m), 2006-2011 27
Table 16: Wound-healing Therapeutics Market, France, Revenue ($m), 2006-2011 28
Table 17: Diabetic Foot Infection Therapeutics Market, France, Forecast ($m), 2011-2019 29
Table 18: Wound-healing Therapeutics Market, France, Forecast ($m), 2011-2019 30
Table 19: Diabetic Foot Infection Therapeutics Market, Germany, Revenue ($m), 2006-2011 31
Table 20: Wound-healing Therapeutics Market, Germany, Revenue ($m), 2006-2011 32
Table 21: Diabetic Foot Infection Therapeutics Market, Germany, Forecast ($m), 2011-2019 33
Table 22: Wound-healing Therapeutics Market, Germany, Forecast ($m), 2011-2019 34
Table 23: Diabetic Foot Infection Therapeutics Market, Italy, Revenue ($m), 2006-2011 35
Table 24: Wound-healing Therapeutics Market, Italy, Revenue ($m), 2006-2011 36
Table 25: Diabetic Foot Infection Therapeutics Market, Italy, Forecast ($m), 2011-2019 37
Table 26: Wound-healing Therapeutics Market, Italy, Forecast ($m), 2011-2019 38
Table 27: Diabetic Foot Infection Therapeutics Market, Spain, Revenue ($m), 2006-2011 39
Table 28: Wound-healing Therapeutics Market, Spain, Revenue ($m), 2006-2011 40
Table 29: Diabetic Foot Infection Therapeutics Market, Spain, Forecast ($m), 2011-2019 41
Table 30: Wound-healing Therapeutics Market, Spain, Forecast ($m), 2011-2019 42
Table 31: Diabetic Foot Infection Therapeutics Market, The UK, Revenue ($m), 2006-2011 43
Table 32: Wound-healing Therapeutics Market, The UK, Revenue ($m), 2006-2011 44
Table 33: Diabetic Foot Infection Therapeutics Market, The UK, Forecast ($m), 2011-2019 45
Table 34: Wound-healing Therapeutics Market, The UK, Forecast ($m), 2011-2019 46
Table 35: Diabetic Foot Infection Therapeutics Market, Japan, Revenue ($m), 2006-2011 47
Table 36: Wound-healing Therapeutics Market, Japan, Revenue ($m), 2006-2011 48
Table 37: Diabetic Foot Infection Therapeutics Market, Japan, Forecast ($m), 2011-2019 49
Table 38: Wound-healing Therapeutics Market, Japan, Forecast ($m), 2011-2019 50
Table 39: Diabetic Foot Ulcer Therapeutics - Phase III Pipeline, 2012 62
Table 40: Diabetic Foot Ulcer Therapeutics - Phase II Pipeline, 2012 63
Table 41: Diabetic Foot Ulcer Therapeutics - Phase I Pipeline, 2012 64
Table 42: Diabetic Foot Ulcer Therapeutics - Preclinical and Discovery Pipeline, 2012 64
Table 43: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials, 2012 72
Table 44: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Phase, 2012 73
Table 45: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Status of Development, 2012 74
Table 46: Diabetic Foot Ulcer Therapeutics, Global, Overall Sponsors, 2012 75
Table 47: Diabetic Foot Ulcer Therapeutics, Global, Prominent Sponsors, 2012 76
Table 48: Diabetic Foot Ulcer Therapeutics, Global, Top Ten Companies by Phase, 2012 77
Table 49: Pfizer, Inc. - Diabetic Foot Ulcer Pipeline Products, 2012 82
Table 50: Cardiovascular Biotherapeutics, Inc. - DFU Pipeline Products, 2012 83
Table 51: HealOr Ltd. - DFU Pipeline Products, 2012 83
Table 52: MacroCure Ltd. - DFU Pipeline Products, 2012 84
Table 53: Diabetic Foot Ulcer Therapeutics - Other Companies in the Pipeline, 2012 84
Table 54: Diabetic Foot Ulcer Therapeutics, Licensing and Partnership Deals, 2012 88
List of Figures
Figure 1: The University of Texas - Diabetic Wound Classification System 9
Figure 2: Diabetic Foot Ulcer - Pathophysiology 14
Figure 3: Diabetic Foot Infections - Antibiotic Use According to Clinical Severity 16
Figure 4: Diabetic Foot Ulcer - Referral Pathway 17
Figure 5: Diabetic Foot Infection Therapeutics Market, Global, Revenue ($m), 2006-2011 19
Figure 6: Wound-healing Therapeutics Market, Global, Revenue ($m), 2006-2011 20
Figure 7: Diabetic Foot Infection Therapeutics Market, Global, Forecast ($m), 2011-2019 21
Figure 8: Wound-healing Therapeutics Market, Global, Forecast ($m), 2011-2019 22
Figure 9: Diabetic Foot Infection Therapeutics Market, The US, Revenue ($m), 2006-2011 23
Figure 10: Wound-healing Therapeutics Market, The US, Revenue ($m), 2006-2011 24
Figure 11: Diabetic Foot Infection Therapeutics Market, The US, Forecast ($m), 2011-2019 25
Figure 12: Wound-healing Therapeutics Market, The US, Forecast ($m), 2011-2019 26
Figure 13: Diabetic Foot Infection Therapeutics Market, France, Revenue ($m), 2006-2011 27
Figure 14: Wound-healing Therapeutics Market, France, Revenue ($m), 2006-2011 28
Figure 15: Diabetic Foot Infection Therapeutics Market, France, Forecast ($m), 2011-2019 29
Figure 16: Wound-healing Therapeutics Market, France, Forecast ($m), 2011-2019 30
Figure 17: Diabetic Foot Infection Therapeutics Market, Germany, Revenue ($m), 2006-2011 31
Figure 18: Wound-healing Therapeutics Market, Germany, Revenue ($m), 2006-2011 32
Figure 19: Diabetic Foot Infection Therapeutics Market, Germany, Forecast ($m), 2011-2019 33
Figure 20: Wound-healing Therapeutics Market, Germany, Forecast ($m), 2011-2019 34
Figure 21: Diabetic Foot Infection Therapeutics Market, Italy, Revenue ($m), 2006-2011 35
Figure 22: Wound-healing Therapeutics Market, Italy, Revenue ($m), 2006-2011 36
Figure 23: Diabetic Foot Infection Therapeutics Market, Italy, Forecast ($m), 2011-2019 37
Figure 24: Wound-healing Therapeutics Market, Italy, Forecast ($m), 2011-2019 38
Figure 25: Diabetic Foot Infection Therapeutics Market, Spain, Revenue ($m), 2006-2011 39
Figure 26: Wound-healing Therapeutics Market, Spain, Revenue ($m), 2006-2011 40
Figure 27: Diabetic Foot Infection Therapeutics Market, Spain, Forecast ($m), 2011-2019 41
Figure 28: Wound-healing Therapeutics Market, Spain, Forecast ($m), 2011-2019 42
Figure 29: Diabetic Foot Infection Therapeutics Market, The UK, Revenue ($m), 2006-2011 43
Figure 30: Wound-healing Therapeutics Market, The UK, Revenue ($m), 2006-2011 44
Figure 31: Diabetic Foot Infection Therapeutics Market, The UK, Forecast ($m), 2011-2019 45
Figure 32: Wound-healing Therapeutics Market, The UK, Forecast ($m), 2011-2019 46
Figure 33: Diabetic Foot Infection Therapeutics Market, Japan, Revenue ($m), 2006-2011 47
Figure 34: Wound-healing Therapeutics Market, Japan, Revenue ($m), 2006-2011 48
Figure 35: Diabetic Foot Infection Therapeutics Market, Japan, Forecast ($m), 2011-2019 49
Figure 36: Wound-healing Therapeutics Market, Japan, Forecast ($m), 2011-2019 50
Figure 37: Diabetic Foot Ulcer Therapeutics Market, Drivers and Barriers, 2012 52
Figure 38: Opportunity and Unmet Need in Diabetic Foot Infection Therapeutics Market, 2012 53
Figure 39: Opportunity and Unmet Need in the Diabetic Foot Ulcer Wound-healing Therapeutics Market, 2012 54
Figure 40: Strategic Competitor Assessment of the Marketed Products in Diabetic Foot Ulcer Therapeutics, 2012 56
Figure 41: Diabetic Foot Ulcer Therapeutics, Clinical Pipeline by Mechanism of Action (%), 2012 65
Figure 42: Diabetic Foot Ulcer Therapeutics, Clinical Pipeline by Phase of Development (%), 2012 66
Figure 43: Technology Trends Analytics Framework, 2012 67
Figure 44: Technology Trends Analytics Framework - Description, 2012 68
Figure 45: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Country, 2012 72
Figure 46: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Phase (%), 2012 73
Figure 47: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Status of Development (%), 2012 74
Figure 48: Diabetic Foot Ulcer Therapeutics, Global, Overall Sponsors (%), 2012 75
Figure 49: Diabetic Foot Ulcer Therapeutics, Global, Prominent Sponsors (%), 2012 76
Figure 50: Diabetic Foot Ulcer Therapeutics, Global, Top Companies by Phase, 2012 77
Figure 51: Diabetic Foot Ulcer Therapeutics Market, Impact Analysis, 2012 78
Figure 52: Implications for Future Market Competition in the Diabetic Foot Ulcer Therapeutics Market, 2012 79
Figure 53: Diabetic Foot Ulcer Therapeutics, Clinical Pipeline by Company, 2012 81
Figure 54: GlobalData Market Size Estimation 93
Figure 55: GlobalData Market Forecasting Model 95
Companies mentioned
Pfizer Inc.
Cardiovascular Biotherapeutics, Inc.
HealOr Ltd.
MacroCure Ltd.
To order this report:
: Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article